Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03139370 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
A Phase 1 study, sponsored by Kite, A Gilead Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03139370 is a Phase 1 study that was terminated before completion, run by Kite, A Gilead Company. The registered enrollment target is 16 participants.
The verdict
NCT03139370, a Phase 1 study, was terminated before completion, sponsored by Kite, A Gilead Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG KITE-718
- DEVICE MAGE - A3/A6 Screening Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2023-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03139370
The ClinicalTrials.gov registry entry for NCT03139370 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03139370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03139370 about?
NCT03139370 is a clinical study titled "Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers". The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.
What is the current status of trial NCT03139370?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-12-27. Estimated completion is 2023-06-04.
What interventions are being tested in trial NCT03139370?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-718 (DRUG), MAGE - A3/A6 Screening Test (DEVICE).
Who is sponsoring clinical trial NCT03139370?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.